Jundishapur Journal of Microbiology

Published by: Kowsar

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Tayebeh Hashempoor 1 , 2 , Amir Mohammad Alborzi 3 , Javad Moayedi 1 , 4 , Mehdi Ajorloo 5 , Taravat Bamdad 6 , Amir Houshang Sharifi 2 , Jean Pierre Lavergne 7 , Arghavan Haj-sheykholeslami 2 and Shahin Merat 2 , *
Authors Information
1 Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
2 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
3 Cancer Research Center of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Comparative Biomedical Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
5 Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
6 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
7 Laboratoire de Bioinformatique et RMN structurales, Institut de Biologie et Chimie des proteines, UMR 5086 CNRS, Universite Claude Bernard Lyon I, Lyon, France
Article information
  • Jundishapur Journal of Microbiology: February 2018, 11 (2); e58294
  • Published Online: January 13, 2018
  • Article Type: Research Article
  • Received: July 27, 2017
  • Revised: October 14, 2017
  • Accepted: December 1, 2017
  • DOI: 10.5812/jjm.58294

To Cite: Hashempoor T, Alborzi A M, Moayedi J, Ajorloo M, Bamdad T, et al. A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus, Jundishapur J Microbiol. 2018 ; 11(2):e58294. doi: 10.5812/jjm.58294.

Copyright © 2018, Jundishapur Journal of Microbiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusion
  • 1. Ajorloo M, Bamdad T, Hashempour T, Alborzi AM, Mozhgani SH, Asadi R, et al. Detection of Specific Antibodies to HCV-ARF/CORE+1 Protein in Cirrhotic and Non-Cirrhotic Patients with Hepatitis C: A Possible Association with Progressive Fibrosis. Arch Iran Med. 2015;18(5):304-7. [PubMed: 25959912].
  • 2. Sarvari J, Mansouri M, Hashempoor T, Hosseini SY, Moattari A, Pirbonyeh N. Association of genotype and haplotype of IL-28B Gene with Hepatitis C infection outcome in iran: Spontaneous clearance versus chronic infection. Hepatit Month. 2017;17(5). e45745. doi: 10.5812/hepatmon.45745.
  • 3. Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol. 2017;206(2):165-74. doi: 10.1007/s00430-017-0497-y. [PubMed: 28214926].
  • 4. Dalagiorgou G, Vassilaki N, Foka P, Boumlic A, Kakkanas A, Kochlios E, et al. High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. J Gen Virol. 2011;92(Pt 6):1343-51. doi: 10.1099/vir.0.023010-0. [PubMed: 21307221].
  • 5. Cohen M, Bachmatov L, Ben-Ari Z, Rotman Y, Tur-Kaspa R, Zemel R. Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection. Dig Dis Sci. 2007;52(9):2427-32. doi: 10.1007/s10620-006-9630-2. [PubMed: 17436105].
  • 6. Bain C, Parroche P, Lavergne JP, Duverger B, Vieux C, Dubois V, et al. Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection. J Virol. 2004;78(19):10460-9. doi: 10.1128/JVI.78.19.10460-10469.2004. [PubMed: 15367612].
  • 7. Hashempour T, Ajorloo M, Bamdad T, Merat S, Zaer-Rezaee H, Fakharzadeh E, et al. Development of a recombinant based ELISA using specific antibodies to f protein in HCV chronically infected patients-a seroprevalence study. Iran J Virol. 2010;4(1):1-6. doi: 10.21859/isv.4.1.1.
  • 8. Sarvari J, Mojtahedi Z, Taghavi SA, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, et al. Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepat Mon. 2013;13(7):8351. doi: 10.5812/hepatmon.8351. [PubMed: 24066001].
  • 9. Gorzin AA, Ramsland PA, Tachedjian G, Gowans EJ. Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle. J Viral Hepat. 2012;19(3):189-98. doi: 10.1111/j.1365-2893.2011.01504.x. [PubMed: 22329373].
  • 10. Hashempour T, Bamdad T, Bergamini A, Lavergne JP, Haj-Sheykholeslami A, Brakier-Gingras L. F protein increases CD4+CD25+ T cell population in patients with chronic hepatitis C. Pathog Dis. 2015;73(4). doi: 10.1093/femspd/ftv022. [PubMed: 25862675].
  • 11. Rahimi P, Vahabpour R, Fard FS, Motevalli F, Chahouki FF, Aghasadeghi MR, et al. Expression of HCV Alternative Reading Frame Protein (Core+1/F) in Baculovirus Expression System and its Evaluation for Assessment of Specific Anti-core+1 Antibody in Iranian HCV Infected Patients. Clin Lab. 2016;62(10):1919-26. doi: 10.7754/Clin.Lab.2016.160205. [PubMed: 28164534].
  • 12. Kassela K, Karakasiliotis I, Charpantidis S, Koskinas J, Mylopoulou T, Mimidis K, et al. High prevalence of antibodies to core+1/ARF protein in HCV-infected patients with advanced cirrhosis. J Gen Virol. 2017;98(7):1713-9. doi: 10.1099/jgv.0.000851. [PubMed: 28708052].
  • 13. Karamitros T, Kakkanas A, Katsoulidou A, Sypsa V, Dalagiorgou G, Mavromara P, et al. Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin. J Viral Hepat. 2012;19(3):182-8. doi: 10.1111/j.1365-2893.2011.01502.x. [PubMed: 22329372].
  • 14. Baril M, Brakier-Gingras L. Translation of the F protein of hepatitis C virus is initiated at a non-AUG codon in a +1 reading frame relative to the polyprotein. Nucleic Acids Res. 2005;33(5):1474-86. doi: 10.1093/nar/gki292. [PubMed: 15755749].
  • 15. Shao SW, Wu WB, Bian ZQ, Yu JG, Zhao P, Zhao LJ, et al. Hepatitis C virus F protein inhibits cell apoptosis by activation of intracellular NF-kappaB pathway. Hepatol Res. 2009;39(3):282-9. doi: 10.1111/j.1872-034X.2008.00452.x. [PubMed: 19054148].
  • 16. Branch AD, Stump DD, Gutierrez JA, Eng F, Walewski JL. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis. 2005;25(1):105-17. doi: 10.1055/s-2005-864786. [PubMed: 15732002].
  • 17. Gao DY, Zhang XX, Hou G, Jin GD, Deng Q, Kong XF, et al. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin. J Clin Microbiol. 2008;46(11):3746-51. doi: 10.1128/JCM.00612-08. [PubMed: 18832124].
  • 18. Xiao W, Jiang LF, Deng XZ, Zhu DY, Pei JP, Xu ML, et al. PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection. Immunol Res. 2016;64(2):412-23. doi: 10.1007/s12026-015-8680-y. [PubMed: 26286967].
  • 19. Pei JP, Jiang LF, Ji XW, Xiao W, Deng XZ, Zhou ZX, et al. The relevance of Tim-3 polymorphisms and F protein to the outcomes of HCV infection. Eur J Clin Microbiol Infect Dis. 2016;35(8):1377-86. doi: 10.1007/s10096-016-2676-y.
  • 20. Kotta-Loizou I, Karakasiliotis I, Vassilaki N, Sakellariou P, Bartenschlager R, Mavromara P. Expression of the novel hepatitis C virus core+1/ARF protein in the context of JFH1-based replicons. J Virol. 2015;89(9):5164-70. doi: 10.1128/JVI.02351-14. [PubMed: 25694591].
  • 21. Park SB, Seronello S, Mayer W, Ojcius DM. Hepatitis C Virus Frameshift/Alternate Reading Frame Protein Suppresses Interferon Responses Mediated by Pattern Recognition Receptor Retinoic-Acid-Inducible Gene-I. PLoS One. 2016;11(7). e0158419. doi: 10.1371/journal.pone.0158419. [PubMed: 27404108].
  • 22. Vassilaki N, Mavromara P. Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/core+1 coding open reading frame. J Biol Chem. 2003;278(42):40503-13. doi: 10.1074/jbc.M305504200. [PubMed: 12874283].
  • 23. Boulant S, Becchi M, Penin F, Lavergne JP. Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from genotype 1b. J Biol Chem. 2003;278(46):45785-92. doi: 10.1074/jbc.M307174200. [PubMed: 12952944].
  • 24. Qureshi H, Qazi R, Hamid S, Qureshi SA. Identification of immunogenic regions within the alternative reading frame protein of hepatitis C virus (genotype 3). Eur J Clin Microbiol Infect Dis. 2011;30(9):1075-83. doi: 10.1007/s10096-011-1194-1. [PubMed: 21318731].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments